Listed

Edwards Lifesciences Corp: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Jul 26, 2019 and accepted by EDGAR at Jul 26, 2019, 16:05 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$1.09bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2019-01-01 to 2019-06-30$2.08bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-04-01 to 2019-06-30$304.0mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2019-01-01 to 2019-06-30$535.8mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2019-04-01 to 2019-06-30$782.9mus-gaap:GrossProfit
Gross profit6 months2019-01-01 to 2019-06-30$1.54bnus-gaap:GrossProfit
Research and development3 months2019-04-01 to 2019-06-30$191.9mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2019-01-01 to 2019-06-30$363.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2019-04-01 to 2019-06-30$308.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2019-01-01 to 2019-06-30$588.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-04-01 to 2019-06-30$267.5mus-gaap:OperatingIncomeLoss
Operating income6 months2019-01-01 to 2019-06-30$541.7mus-gaap:OperatingIncomeLoss
Income tax3 months2019-04-01 to 2019-06-30$29.0mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2019-01-01 to 2019-06-30$57.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-04-01 to 2019-06-30$242.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income6 months2019-01-01 to 2019-06-30$492.0mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2019-04-01 to 2019-06-30$1.14us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2019-01-01 to 2019-06-30$2.32us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-04-01 to 2019-06-30$1.16us-gaap:EarningsPerShareBasic
Basic EPS6 months2019-01-01 to 2019-06-30$2.37us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-04-01 to 2019-06-30212,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2019-01-01 to 2019-06-30212,100,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2019-01-01 to 2019-06-30$342.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2019-01-01 to 2019-06-30$106.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2019-01-01 to 2019-06-30$262.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-06-30$726.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$2.35bnus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$5.57bnus-gaap:Assets
Current liabilitiesAt period end2019-06-30$697.0mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2019-06-30$594.1mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2019-06-30$3.50bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-19-000019. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.